TY - JOUR
T1 - Haemodynamic definitions and updated clinical classification of pulmonary hypertension
AU - Simonneau, Gérald
AU - Montani, David
AU - Celermajer, David S.
AU - Denton, Christopher P.
AU - Gatzoulis, Michael A.
AU - Krowka, Michael
AU - Williams, Paul G.
AU - Souza, Rogerio
N1 - Funding Information:
Conflict of interest: G. Simonneau reports grants, personal fees and non-financial support from Actelion Pharmaceuticals, Bayer Healthcare, Merck and GSK, outside the submitted work. D. Montani reports grants, personal fees and non-financial support from Actelion Pharmaceuticals, Bayer Healthcare, Merck and GSK, outside the submitted work. D.S. Celermajer is an investigator on two clinical trials sponsored by Actelion. C.P. Denton reports grants and personal fees from Actelion and Roche, grants from GSK, and personal fees from Bayer and Boehringer Ingelheim, during the conduct of the study; grants and personal fees from Inventiva and CSL Behring, and personal fees from Leadiant, outside the submitted work. M.A. Gatzoulis reports personal fees for steering committee membership from Actelion Pharmaceuticals, and grants from Actelion Global, Pfizer and GSK, during the conduct of the study. M. Krowka is a steering committee member for PORTICO (Macitentan for Portopulmonary Hypertension Study), which is sponsored by Actelion, outside the submitted work. P.G. Williams received personal fees for advisory board meetings from Aspen SA and GSK, outside the submitted work. R. Souza reports lecture and consultancy fees from Actelion, Bayer, GSK and Pfizer, outside the submitted work.
Publisher Copyright:
Copyright © ERS 2019. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±3.3 mmHg. Two standard deviations above this mean value would suggest mPAP >20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH associated with mPAP >20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management. Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup “pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers”, due to the specific prognostic and management of these patients, and a subgroup “PAH with overt features of venous/ capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement”, due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH.
AB - Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±3.3 mmHg. Two standard deviations above this mean value would suggest mPAP >20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH associated with mPAP >20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management. Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup “pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers”, due to the specific prognostic and management of these patients, and a subgroup “PAH with overt features of venous/ capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement”, due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH.
UR - http://www.scopus.com/inward/record.url?scp=85060524284&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060524284&partnerID=8YFLogxK
U2 - 10.1183/13993003.01913-2018
DO - 10.1183/13993003.01913-2018
M3 - Article
C2 - 30545968
AN - SCOPUS:85060524284
SN - 0903-1936
VL - 53
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 1
M1 - 1801913
ER -